ArticleCancers2022

Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study.

Renaud Descourt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.